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Pompe disease (OMIM 232300) is an AR glycogenosis due
to deficiency of the lysosomal enzyme alpha-glucosidase
(GAA). As a result, glycogen storage occurs in muscles
and patients present a wide clinical spectrum ranging
from early onset severe cardiomyopathy (EOPD) to adult
onset forms (LOPD). Severe loss of GAA activity corre-
lates with early onset and severe phenotypes. Residual
enzyme activity warrants later onset and a slowly progres-
sive course, although a strict correlation is not always
observed. Patients with Classic infantile Pompe disease
show hypotonia, macroglossia, respiratory insufficiency
and early death for cardiorespiratory failure.
The availability of enzyme replacement therapy (ERT)
with alglucosidase alfa ( human recombinant GAA) has
changed the natural history of the disease allowing most
children with EOPD a longer survival and a longer pre-
served muscle performance with increased quality of life
in LOPD.
The experience of the Regional referral Center for Meta-
bolic Diseases, University of Catania, concerns 11 patients
(9 months to 65 years at the time of the diagnosis). Their
clinical and laboratory follow-up included eye tracking
and Muscle MRI.
EOPD, with a severe clinical picture since the first
weeks of life and cardiomyopathy was observed in a
newborn who died at age 4 months, despite early started
and high dosage ERT. Another girl with EOPD is on
ERT since the age of 9 months and, today, after 7 years
of treatment shows only mild signs of muscle weakness
and no cardiac involvement.
Five more LOPD patients on ERT had a significant
improvement of blood parameters including transaminases,
LDH and CPK. No progression of muscle impairment was
seen after 5 to 8 years of treatment, except for one 35 years
old man, who was already severely compromised and did
not show any benefit in terms of respiratory ventilation.
In a recently performed Italian survey of classical
Pompe disease treated with ERT, a substantial improve-
ment in cardiac parameters and gross motor function
was observed, even if residual muscle weakness still exist
and gross motor function remain below age-appropriate
levels.
The different response to ERT depends on several factors
mainly on timing of treatment (worse outcome if started
later than 5 months of age) and cross reactive immune
material (CRIM-negative status associated with less good
response to ERT).
Although some residual mild weakness is present in
treated patients, ERT has demonstrated its effects on
respiration, lowering nocturnal apneas and allowing
patients a better quality of life.
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